Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Erlangen-Nürnberg Medical School
University of Kentucky
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
University of California, San Diego
Mayo Clinic
MacroGenics
Flamingo Therapeutics NV
Emory University
University of Michigan Rogel Cancer Center
University of Pittsburgh
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
Gilead Sciences
Washington University School of Medicine
Medical University of South Carolina
Dana-Farber Cancer Institute
University of Southern California
M.D. Anderson Cancer Center
Sanofi
Calliditas Therapeutics AB
GERCOR - Multidisciplinary Oncology Cooperative Group
Yale University
University of California, San Diego
Dana-Farber Cancer Institute
University of Chicago
Regeneron Pharmaceuticals
University of Chicago
Thomas Jefferson University
Medical College of Wisconsin
Bayer
Washington University School of Medicine
West Virginia University
Seagen Inc.
University of Pittsburgh
Eastern Cooperative Oncology Group
City of Hope Medical Center
University of Pittsburgh
Hospital of Stomatology, Wuhan University
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Immutep S.A.S.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco